噻托溴铵治疗慢性阻塞性肺疾病患者的临床疗效及安全性.docVIP

噻托溴铵治疗慢性阻塞性肺疾病患者的临床疗效及安全性 　　【摘要】目的探讨噻托溴铵治疗慢性阻塞性肺疾病（COPD）患者的临床疗效及安全性。 　　方法将94例COPD患者随机分为观察组48例和对照组46例，对照组给予常规治疗，观察组给予常规治疗加用噻托溴铵吸入治疗，观察两组患者肺功能变化及用药过程的不良反应，并评价临床疗效。 　　结果经治疗4周后、8周后，观察组的临床疗效均明显优于对照组（P0.05）。与治疗前相比较，观察组经治疗4周后、8周后FEV1、FVC、FEV1/FVC均逐步升高（P0.01），对照组经治疗4周后、8周后FVC、FEV1/FVC均逐步升高（P0.05或0.01）。治疗4周后、8周后观察组的FEV1、FVC、FEV1/FVC均高于对照组（P0.01）。用药期间两组均未发生明显不良反应。 　　结论噻托溴铵能明显改善COPD患者肺功能、提高治疗效果，且无明显不良反应。 　　【关键词】噻托溴铵；慢性阻塞性肺疾病；临床疗效；安全性 　　中图分类号：R563文献标识码：ADOI：10.3969/j.issn2017.01.014 　　Clinical efficacy and safety of tiotropium bromide for patients with chronic obstructive pulmonary disease 　　[HJ2][HJ] 　　QIN Jianmin，TANG Yanmei，JI Zhen，LU Jian 　　（The First People’s Hospital of Hechi，Hechi 546300，China） 　　[HJ2][HJ] 　　【Abstract】ObjectiveTo explore clinical efficacy and safety of tiotropium bromide for patients with chronic obstructive pulmonary disease（COPD）. 　　MethodsA total of 94 patients with COPD were randomly divided into observation group（n=48） and control group（n=46）.The control group were treated with conventional therapy，and the observation group were treated by conventional therapy combined with tiotropium bromide.The changes of pulmonary function and adverse reactions of the two groups were observed，and the clinical effects were evaluated. 　　ResultsAfter 4 weeks and 8 weeks of treatment，the clinical effect in the observation group was significantly better than that in the control group（P0.05）.Compared with those before treatment，FEV1， FVC and FEV1/FVC of the observation group increased gradually （P0.01），so did FVC and FEV1/FVC of the control group（P0.05 or 0.01）.In addition，after 4 weeks and 8 weeks of treatment，FEV1，FVC and FEV1/FVC of the observation group were all significantly higher than those of the control group（P0.01）.There were no obvious adverse reactions in the two groups during treatment. 　　ConclusionTiotropium bromide can obviously improve pulmonary function and raise the clinical effects for patients with COPD，it has no severe adve